Germany – cancer vaccine
It is called an alternative to chemotherapy. The vaccine, which the pharmaceutical company BioNTech is developing, will help cure cancer patients in the future, according to the company’s CEO, Ugur Sahin, ZDF and Euroinvestor reported. “We expect our first mRNA-based cancer vaccine to be approved by 2030,” he said. As the vaccine is developed on the basis of the relatively new mRNA technology, it will contain small genetic codes that will teach the body to fight cancer cells on its own. In the general public BioNTech is probably best known for being behind one of the coronavirus vaccines. It was based on the same technology. At that time, a lot of experience was gained, which will now help the company develop the cancer vaccine, writes Euroinvestor./ritzau/